127
Participants
Start Date
January 15, 2022
Primary Completion Date
May 24, 2024
Study Completion Date
June 30, 2026
Evorpacept (ALX148)
IV Q2W
Trastuzumab
IV Q2W
Ramucirumab
IV Q2W
Paclitaxel
IV Days 1, 8, and 15 of a 28-day cycle
Koo Foundation Sun Yat-Sen Cancer Center, Beitou
Taipei Veterans General Hospital, Taipei
National Cheng Kung University Hospital, Tainan City
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Universitair Ziekenhuis Antwerpen, Antwerp
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven
Monash Medical Centre, Clayton
Centre Hospitalier Universitaire de Liège, Liège
Icon Cancer Centre Southport, Southport
National Taiwan University Hospital, Taipei
National Cancer Center - Korea, Goyang-si
Korea University Guro Hospital, Seoul
Vseobecna Fakultni Nemocnice v Praze, Prague
Institut Paoli-Calmettes, Marseille
Seoul National University Bundang Hospital, Seongnam
Hospital Universitario Reina Sofía, Córdoba
Hallym University Sacred Heart Hospital, Dongan
The Catholic University of Korea Saint Vincent's Hospital, Suwon
Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
NEXT Virginia, Fairfax
Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz, Besançon
Hospital Universitario Lucus Augusti, Lugo
Hospital Universitario Ramón y Cajal, Madrid
Hôpital Morvan, Brest
Hôpital Rangueil, Toulouse
Centre Hospitalier Universitaire de Bordeaux, Bordeaux
Azienda Sanitaria Universitaria Friuli Centrale - P.O. Santa Maria della Misericordia, Udine
Chungnam National University Hospital, Daejeon
Vanderbilt University Medical Center, Nashville
Hospital Universitario Marqués de Valdecilla, Santander
China Medical University Hospital, Taichung
Yeungnam University Medical Center, Daegu
Inje University Haeundae Paik Hospital, Busan
Dong-A University Hospital, Busan
Pusan National University Hospital, Busan
Hospital Universitario Miguel Servet, Zaragoza
Azienda Ospedaliero - Universitaria Careggi, Florence
Centre Léon Bérard, Lyon
Hôpital Privé Jean Mermoz, Lyon
Chi Mei Hospital - Liouying, Tainan City
Hôpital Saint-Antoine, Paris
Hôpital Trousseau, Paris
University of California Los Angeles, Los Angeles
The Oncology Institute of Hope & Innovation, Anaheim
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania
Fred Hutchinson Cancer Center, Seattle
National Cancer Centre Singapore, Singapore
Icon Cancer Centre Farrer Park, Singapore
Fakultní Nemocnice Hradec Králové, Hradec Králové
Fakultní Nemocnice Olomouc, Olomouc
Policlinico Universitario Campus Bio-Medico, Roma
National Cancer Center Hospital East, Chiba
Kyushu Cancer Center, Fukuoka
Gifu University Hospital, Gifu
Japanese Red Cross Kumamoto Hospital, Kumamoto
University Hospital Kyoto Prefectural University of Medicine, Kyoto
Nagasaki University Hospital, Nagasaki
Osaka Prefectural Hospital Organization - Osaka International Cancer Institute, Osaka
Kindai University Hospital, Osaka
Oita University Hospital - Hasama Campus, Ōita
Saitama Cancer Center, Saitama
Tohoku University Hospital, Sendai
Shizuoka Cancer Center, Shizuoka
National Cancer Center Hospital, Tokyo
Cancer Institute Hospital of JFCR, Tokyo
Kanagawa Cancer Center, Yokohama
Jeonbuk National University Hospital, Jeonju
Korea University Anam Hospital, Seoul
Seoul National University Hospital, Seoul
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul
Asan Medical Center, Seoul
Gangnam Severance Hospital, Seoul
Severance Hospital, Seoul
Samsung Medical Center, Seoul
Boramae Medical Center, Seoul
Hospital General Universitario de Elche, Alicante
Hospital Germans Trias i Pujol, Badalona
Hospital Quirónsalud Barcelona, Barcelona
Hospital Universitari Vall d'Hebrón, Barcelona
Hospital Clinic de Barcelona, Barcelona
Royal Free Hospital, London
Guy's and Saint Thomas' NHS Foundation Trust, London
The Royal Marsden Hospital, London
Lead Sponsor
Eli Lilly and Company
INDUSTRY
ALX Oncology Inc.
INDUSTRY